From GlobeNewswire: 2025-06-21 08:00:00

Perspective Therapeutics, Inc. has reached an agreement with the FDA to open the third dosing cohort (Cohort 3) of its Phase 1/2a clinical trial for [212Pb]VMT-α-NET. Patients in Cohort 3 will receive a higher dose of 6 mCi, up to 20% more than the previous dose, to assess potential therapeutic benefits and safety. The Company plans to submit updates on clinical data to scientific congresses in the second half of 2025, including safety follow-up and anti-tumor activities in patients dosed with [212Pb]VMT-α-NET. Cohort 3 is now open for recruitment, with a focus on monitoring dose-limiting toxicities and exploring alternative dosing strategies. Perspective is pioneering advanced treatments for cancers using its proprietary technology that delivers radiation specifically to cancer cells. The Company’s theranostic approach combines imaging diagnostics and therapy to personalize treatment and improve patient outcomes. The Phase 1/2a study of [212Pb]VMT-α-NET is moving into Cohort 3 with a higher fixed dose of 6 mCi. A dosimetry sub-study analysis was presented at the SNMMI 2025 Annual Meeting to enhance clinical development. Further clinical updates will be submitted to scientific congresses in 2H 2025, including safety follow-up and anti-tumor activities. Forward-looking statements in the news release are current as of the date. Media and Investor Relations Contacts: Perspective Therapeutics IR – Annie J. Cheng, CFA ([email protected]) and Russo Partners, LLC – Nic Johnson ([email protected]).



Read more at GlobeNewswire: Perspective Therapeutics Commences Recruitment for